BGM Associates has assisted DuChemBio Co. Ltd. and Accera, Inc. to bring the proprietary medium chain triglyceride (MCT) technology to South Korea.
Accera, a leading CNS therapeutic company is focused on pioneering novel therapeutic approaches to treat neurodegenerative diseases caused by metabolic deficiencies, such as regional decreases in cerebral glucose metabolism associated with Alzheimer’s disease (see illustration). Accera’s proprietary MCT technology addresses this issue by providing the brain with ketone bodies, a natural alternative fuel to glucose.
DuChemBio has been active in the field of neurodegenerative diseases since 2012, primarily through commercializing nuclear medicine biomarkers for the diagnosis of Alzheimer’s and Parkinson’s diseases. BGM Associates is supporting DuChemBio in its endeavor to fully develop and commercialize Accera’s technology.
Link to press release
Accera, a leading CNS therapeutic company is focused on pioneering novel therapeutic approaches to treat neurodegenerative diseases caused by metabolic deficiencies, such as regional decreases in cerebral glucose metabolism associated with Alzheimer’s disease (see illustration). Accera’s proprietary MCT technology addresses this issue by providing the brain with ketone bodies, a natural alternative fuel to glucose.
DuChemBio has been active in the field of neurodegenerative diseases since 2012, primarily through commercializing nuclear medicine biomarkers for the diagnosis of Alzheimer’s and Parkinson’s diseases. BGM Associates is supporting DuChemBio in its endeavor to fully develop and commercialize Accera’s technology.
Link to press release
